Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL
Takahashi, S.
Clinical Calcium 21(3): 447-453
2011
ISSN/ISBN: 0917-5857 PMID: 21358067 Document Number: 652396
Various cancer treatments can cause gonadal dysfunction and bone loss. Especially, endocrine therapies for breast cancer or prostate cancer carry a significant risk of cancer treatment-induced bone loss (CTIBL) . LHRH agonist- or chemotherapy-induced premature menopause in premenopausal breast cancer patients, aromatase inhibitor in postmenopausal breast cancer patients, and LHRH agonist with or without anti-androgen in prostate cancer patients may cause bone loss of 5% or more within several years. Oral or intravenous bisphosphonates are effective for prevention of CTIBL, and RANKL antibody (denosumab) is also effective. During treatment, physicians should follow bone mineral density and avoid QOL impairment due to osoteoporosis.